Last Updated : May 2, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Genvoya | Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | HIV infection | List | Complete | ||
| Stribild | Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Disoproxil Fumarate | HIV infection | List with criteria/condition | Complete | ||
| Viberzi | eluxadoline | Irritable bowel syndrome with diarrhea | Do not reimburse | Complete | ||
| Revolade | Eltrombopag olamine | Chronic immune thrombocytopenic purpura | Do not list | Complete | ||
| Revolade | eltrombopag | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| N/A | eltrombopag | Severe Aplastic Anemia (SAA) | Reimburse with clinical criteria and/or conditions | Active | ||
| Revolade | Eltrombopag | Thrombocytopenia associated with chronic hepatitis c infection | List with criteria/condition | Complete | ||
| Elrexfio | elranatamab | Relapsed or refractory multiple myeloma | Active | |||
| Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Do not list | Complete |
Last Updated : May 2, 2024